A study from researchers at MD Anderson Cancer Center indicates that mutations found in cancers do not accumulate randomly, but are found in distinct patterns that vary based on the three-dimensional organization of the genome in the cell as well as the underlying factors causing the mutations.
Researchers at the University of California San Diego School of Medicine found that patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy.
The phase III CheckMate-816 trial met a primary endpoint of pathologic complete response in resectable non-small cell lung cancer.
An international team led by clinician-scientists at UPMC and the University of Pittsburgh School of Medicine have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness.
Bristol Myers Squibb said CheckMate -274, a pivotal phase III trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).
Treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival in patients with early-stage, non-small cell lung cancer with epidermal growth factor receptor gene mutation, according to updated findings led by researchers at Yale Cancer Center.
One in seven Black women with breast cancer had delays in starting treatment, and Black women also had extended duration of treatment, according to a study led by UNC Lineberger Comprehensive Cancer Center researchers.
A study led by researchers at Fred Hutchinson Cancer shows that iCanQuit app is one-and-a-half times more efficacious than the NCI QuitGuide app.
The phase III EORTC1325/KEYNOTE-054 trial evaluating Keytruda as adjuvant therapy in resected, high-risk stage III melanoma, met the key secondary endpoint of distant metastasis-free survival.
The phase III KEYNOTE-590 trial evaluating Keytruda in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer demonstrated a significant improvement in overall survival.